Medicine & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Aerovance, Inc.
Aerovance secures $60 million in financing
June 2nd, 2006
Aerovance, Inc., a biopharmaceutical company with a portfolio of clinical-stage drugs targeting severe respiratory and inflammatory diseases, announced it has secured $60 million in series C financing. Led by Clarus Ventures, the financing round, which consists of two tranches, includes participation from Alta Partners as well as Aerovance's current investors: Apax Partners, Lehman Brothers, NGN Capital and Burrill & Co. Aerovance has received $28 million and will receive an additional $32 million upon meeting certain clinical, manufacturing and other milestones. With this financing, the company, which was spun out of Bayer Pharmaceutical Corp. in 2004, will have...
Source: Medicine & Law Weekly (2006-06-02)
|
